New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
16:26 EDTF, XOM, BCOV, TM, GM, MRK, ABAX, FIATY, CVX, LTM, ADNCOn The Fly: Closing Wrap
Stocks on Wall Street were higher on the day after the monthly jobs and manufacturing reports topped expectations, and the Dow Jones Industrial Average closed above 14,000 for the first time since October 2007... ECONOMIC EVENTS: In the U.S., the nonfarm payrolls report showed that 157K jobs were added in January and unemployment rose to 7.9%. This compared to expectations for 165K new jobs and for unemployment to hold steady at 7.8%. Notably, December payroll additions were revised up to 196K from 155K and November was raised to 247K from 161K. The University of Michigan consumer confidence reading for January came in at 73.8, versus the expected 71.5. The January ISM manufacturing index had a reading of 53.1, versus the expected reading of 50.7, while Markit's January U.S. PMI came in at 55.8, also beating expectations. Construction spending in the month of December rose 0.9%, versus the expected increase of 0.7%. In China, the government’s official PMI slid to 50.4 from 50.6 in December, while a similar PMI reading from HSBC rose to a two-year high of 52.3. In Europe, the euro zone PMI hit an 11-month high at 47.9, though that figure is still indicates contraction... COMPANY NEWS: Among Dow members reporting earnings before the bell were Merck (MRK), ExxonMobil (XOM), and Cevron (CVX). Merck, which reported in-line EPS and revenue was the average's laggard after the company announced it would delay its filing for approval of odanacatib, its investigational osteoporosis drug, and shares were down $1.42, or 3.28%, to $41.83. Shares of ExxonMobil were up slightly, adding 7c, or 0.08%, to $90.04, while shares of Chevron gained $1.35, or 1.17%, to $116.50... General Motors (GM), Ford (F), Chrysler (FIATY) and Toyota (TM) all reported double-digit sales increases in January... MAJOR MOVERS: Among those moving higher following earnings were Audience (ADNC), up $1.88, or 15.38%, to $14.10, and Abaxis (ABAX), up $5.57, or 14.39%, to $44.29 after earnings beat estimates and shares were upgraded to Strong Buy from Buy at Feltl with a $49 price target... Among noteworthy losers were shares of Brightcove (BCOV), down $2.31, or 27.43%, to $6.11 after the company cut its Q1 and FY13 guidance and shares were downgraded to Outperform from Top Pick at RBC Capital with a $16 price target. Also lower were shares of Life Time Fitness (LTM), down $11.37, or 22.41%, to $39.36 after the company's preliminary Q4 results were lower that current estimates and the company cut its FY12 and FY13 EPS view, and shares were also downgraded by at least three firms... INDICES: The Dow was up 149.21, or 1.08%, to 14,009.79; the S&P 500 15.06, or 1.01%, to 1,513.17; the Nasdaq was up 36.97, or 1.18%, to 3,179.10.
News For MRK;XOM;CVX;GM;F;FIATY;TM;ADNC;ABAX;BCOV;LTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 8, 2015
07:33 EDTMRKAdvaxis, Merck begin enrollment in Phase 1/2 of ADJX-PSA with Keytruda
Advaxis (ADXS) and Merck (MRK) announced that enrollment has initiated in the Phase 1/2 clinical trial evaluating the combination of ADXS-PSA, an investigational Lm-LLO immunotherapy, and Keytruda, the first anti-PD-1 therapy approved in the United States, in patients with previously treated, metastatic castration-resistant prostate cancer, or mCRPC. The clinical trial, KEYNOTE-046, is the first-in-human study of Advaxis's lead Lm-LLO immunotherapy candidate for prostate cancer. It is the second study initiated to evaluate the use of KEYTRUDA in the treatment of advanced prostate cancer. ADXS-PSA and KEYTRUDA are members of a class of cancer treatments known as immuno-oncology therapies. Data from preclinical studies suggest that Advaxis Lm-LLO immunotherapies in combination with a PD-1 antibody may lead to an enhanced anti-tumor immune response. The results from KEYNOTE-046 will determine the future clinical development program for the combination.
07:04 EDTMRKMerck's investigational Hep C therapy granted breakthrough therapy designations
Subscribe for More Information
April 7, 2015
11:27 EDTGMCanadian sale of General Motors stake removes an overhang, says BofA/Merrill
Subscribe for More Information
10:05 EDTTMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTGMOn The Fly: Pre-market Movers
Subscribe for More Information
09:06 EDTCVXChevron launches new category of heavy duty motor oil in Canada
Subscribe for More Information
09:01 EDTGMGeneral Motors 73.39M share Block Trade priced at $35.90
Subscribe for More Information
07:14 EDTMRKEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
06:56 EDTGMGeneral Motors 73.39M share Block Trade; price range $35.80-$36.00
Subscribe for More Information
06:43 EDTXOM, CVXOil retreats on reports of Iran, China talks, Reuters says
Subscribe for More Information
06:40 EDTXOMExxon, NJ settlement controversy to continue, WSJ says
Subscribe for More Information
06:38 EDTTMToyota downgraded to Neutral from Buy at UBS
April 6, 2015
18:01 EDTGMCanada GEN Investment to sell 73.39M shares of General Motors to Goldman Sachs
Subscribe for More Information
11:41 EDTGMDeath claims linked to GM ignition switches up to 80, WSJ reports
The number of deaths linked to General Motors' faulty ignition switch was raised by three to 80 total people, reports The Wall Street Journal, citing statements by lawyers operating the GM compensation fund. The number of confirmed injury claims rose by seven to 141 people. Reference Link
07:41 EDTGMBrookings Institute to hold a discussion
Subscribe for More Information
06:41 EDTXOM, CVXOil up after Saudi Arabia increases prices for Asia, Reuters says
Subscribe for More Information
05:54 EDTTMToyota to open plants in Mexico and China, Financial Times reports
Subscribe for More Information
April 5, 2015
18:12 EDTXOM, CVXOil falls after tentative nuclear deal for Iran, Reuters says
After a preliminary pact between Iran and world powers on Tehran's nuclear program the price of Brent oil fell nearly 4% on Thursday, says Reuters. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
15:52 EDTFNHTSA to reopen investigation into Ford sedan exterior lighting failures
Subscribe for More Information
08:43 EDTGMAT&T, Philip Morris, eight others have reliable yields up to 5.7%, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use